ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0070849;response to epidermal growth factor;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;24.053434438352202;5.9928839937622085;8.050468039660755E-4;0.5967173779995258;[TPR]
GO:1900131;negative regulation of lipid binding;5.0;1.0;0.7902410118609202;9.628524252492122;30.924316076013906;9.777073627680469;0.0010350090289865986;0.7902410118609202;[PEX19]
GO:1990090;cellular response to nerve growth factor stimulus;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;97.48528473772916;5.9928839937622085;0.003262744749111514;0.6295966787287501;[CIB1]
GO:0007250;activation of NF-kappaB-inducing kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1337.9940718610228;6.8867018697843045;0.04478145746870162;0.8003065664753022;[ZFP91]
GO:0036010;protein localization to endosome;6.0;0.8653626801206646;0.7558016526504768;9.405380701177911;32.77360880529348;7.474488534686424;0.001096903192380182;0.7053660038532718;[TMEM30A]
GO:0008344;adult locomotory behavior;3.0;0.8436909121759173;0.6199657686781032;9.158520623246385;24.575257889458463;5.459585514144159;8.225117652639858E-4;0.47732376968016754;[PAFAH1B1, ARCN1]
GO:0051091;positive regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.431813958246067;277.8307104044464;4.2636448815154875;0.00929874384583087;0.650471949850128;[UBE2I, CIB1]
GO:0051092;positive regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.4401483168805;4.8283137373023015;0.009352610284359957;0.6950405016553352;[CIB1]
GO:1900017;positive regulation of cytokine production involved in inflammatory response;8.0;1.0;0.875;9.628524252492122;226.66426644256094;7.004484905440688;0.0075862490132365176;0.7332096838060964;[KARS]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[KARS]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[UBE2I, CNOT1, NFIC, SAP130, TPR, DPF2, ZNF564]
GO:0000184;nuclear-transcribed mRNA catabolic process, nonsense-mediated decay;10.0;0.8933024483968273;0.861892236059334;9.57851383191746;717.2549128915896;4.989581884898423;0.0240058764469685;0.6704084614939124;[SMG5]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[KARS, NFIC, DPF2, DVL3, DDX41, AATF, ZNF564]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[RIC8A, ALS2, EIF4E2, SEC24C]
GO:0017185;peptidyl-lysine hydroxylation;9.0;0.8259837884571596;0.8092325194088689;9.383401794459138;311.1531205407288;7.697632086000634;0.01041401492487012;0.7898978880348613;[VPS33B]
GO:0000060;protein import into nucleus, translocation;9.0;1.0;0.896240625180289;9.628524252492122;93.4429707305496;6.444869117505266;0.0031274521371376313;0.7258315315665724;[TNPO2]
GO:0001947;heart looping;7.0;1.0;0.8509193652572005;9.628524252492122;47.98143023837329;5.71663061713405;0.001605895289594654;0.6432681208679463;[TMED2]
GO:0070966;nuclear-transcribed mRNA catabolic process, no-go decay;10.0;1.0;0.9152410118609203;9.628524252492122;717.2549128915896;8.67846133901236;0.0240058764469685;0.8590579283277371;[CNOT6]
GO:0050679;positive regulation of epithelial cell proliferation;6.0;0.7192862368539868;0.682763431017138;8.647694999480395;65.06748660449396;4.584116776790259;0.002177750219716307;0.5575522577384293;[WDR48]
GO:0034063;stress granule assembly;7.0;1.0;0.8509193652572005;9.628524252492122;107.30488678463786;7.069023426578259;0.0035913979925534566;0.7124295520356204;[ATXN2]
GO:0071805;potassium ion transmembrane transport;9.0;0.8259837884571596;0.8092325194088689;9.456673995565463;120.6235085317852;4.695669262696007;0.004037160276449102;0.636377369645515;[SLC9A6]
GO:0065003;protein-containing complex assembly;4.0;0.45485133202666184;0.4774256660133309;6.058991556010752;36.471478728154885;2.4440506132939883;0.0012206675708314864;0.3749888620238313;[ATXN2, PDCD6IP, KCTD10, TUBGCP2, TMED2, VAMP4, SEC24C]
GO:0007264;small GTPase mediated signal transduction;6.0;0.7369933605727446;0.6916169928765168;8.741221057491218;26.42836680105094;4.015022244900292;8.845336528452411E-4;0.5284487369119741;[ALS2, DOCK2]
GO:0007026;negative regulation of microtubule depolymerization;10.0;0.8933024483968273;0.861892236059334;9.54514264355307;364.4217241224184;6.599019797332524;0.012196867148118488;0.7527151911823093;[CIB1]
GO:0007268;chemical synaptic transmission;7.0;0.7369933605727446;0.7194160455435727;8.663443356448536;23.173347188538074;3.922001705478042;7.755910757418987E-4;0.5514907148670789;[ALS2, PAFAH1B1]
GO:0042144;vacuole fusion, non-autophagic;6.0;1.0;0.8231203125901445;9.628524252492122;61.09264113444484;9.777073627680469;0.002044715718962439;0.8231203125901445;[VPS41]
GO:0045773;positive regulation of axon extension;11.0;0.8933024483968273;0.8790801765280758;9.582004236857228;1257.908905926367;6.113511981550823;0.04210107903683872;0.7450742393735527;[PAFAH1B1]
GO:0045653;negative regulation of megakaryocyte differentiation;8.0;1.0;0.875;9.628524252492122;350.11976986482637;8.16763571524637;0.011718193610040062;0.7926932703116032;[CIB1]
GO:1900026;positive regulation of substrate adhesion-dependent cell spreading;8.0;1.0;0.875;9.628524252492122;350.51777089970517;6.280566066213989;0.011731514346499779;0.6961884407023742;[CIB1]
GO:0006611;protein export from nucleus;9.0;0.7508913569872202;0.7716863036738992;9.277126365654233;128.4390295807893;5.948432231191374;0.00429873873244698;0.7004437261138039;[AHCYL1]
GO:0006974;cellular response to DNA damage stimulus;4.0;0.5696777571895439;0.534838878594772;7.469040003138749;28.997869804256865;3.161008442547652;9.705326059599744E-4;0.4116541187538124;[CNOT6, WDR48, CNOT1, CASP2, CIB1, CNOT10, AATF]
GO:0021540;corpus callosum morphogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;69.80210411808247;8.16763571524637;0.002336213607016992;0.8501222226412654;[PAFAH1B1]
GO:0006730;one-carbon metabolic process;3.0;0.8933024483968273;0.6447715367885581;9.292052015870908;26.874295102004712;6.518977089658987;8.994584717687482E-4;0.5315011041187423;[AHCYL1]
GO:1903779;regulation of cardiac conduction;7.0;0.6913464685778243;0.6965925995461126;8.763526815005518;28.828680454715183;5.788089581116195;9.648699906913433E-4;0.6469225356091749;[AHCYL1]
GO:0006610;ribosomal protein import into nucleus;10.0;1.0;0.9152410118609203;9.628524252492122;278.22868408041535;7.697632086000634;0.009312063666612497;0.8088982747154926;[TNPO2]
GO:0060117;auditory receptor cell development;6.0;1.0;0.8231203125901445;9.628524252492122;70.66252087732656;8.16763571524637;0.002365010981624082;0.7408135829017477;[PAFAH1B1]
GO:0001954;positive regulation of cell-matrix adhesion;6.0;0.8653626801206646;0.7558016526504768;9.34084218004034;50.25702962731741;5.926926025970411;0.0016820575532361247;0.6262235851885184;[CIB1]
GO:0006607;NLS-bearing protein import into nucleus;10.0;1.0;0.9152410118609203;9.628524252492122;278.22868408041535;6.481236761676141;0.009312063666612497;0.7466917612613706;[TNPO2]
GO:0070830;bicellular tight junction assembly;6.0;1.0;0.8231203125901445;9.628524252492122;56.140948375987016;6.280566066213989;0.001878987018571015;0.6443087532925187;[PDCD6IP]
GO:0018146;keratan sulfate biosynthetic process;8.0;1.0;0.875;9.628524252492122;415.40755540718914;6.409777797693995;0.013903317036950667;0.7027963346592216;[SLC35D2]
GO:0034058;endosomal vesicle fusion;7.0;1.0;0.8509193652572005;9.628524252492122;65.8060249050737;7.474488534686424;0.0022024684319953925;0.7331650565203278;[VPS41]
GO:0051415;microtubule nucleation by interphase microtubule organizing center;8.0;1.0;0.875;9.628524252492122;35.68306959426445;7.9853141584524145;0.001194280226642328;0.7833693374183408;[TUBGCP2]
GO:0106101;ER-dependent peroxisome localization;7.0;1.0;0.8509193652572005;9.628524252492122;53.42698937267743;9.777073627680469;0.001788153253134772;0.8509193652572005;[PEX16]
GO:0051898;negative regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.79440420981607;6.063501560976162;0.00799223380789131;0.6850877518099798;[CIB1]
GO:0035264;multicellular organism growth;3.0;1.0;0.6981203125901445;9.628524252492122;22.582921643529833;5.382624473008031;7.558300640989654E-4;0.47338797845741154;[WDR48, TMED2]
GO:0035022;positive regulation of Rac protein signal transduction;10.0;1.0;0.9152410118609203;9.628524252492122;338.93141114640116;8.67846133901236;0.01134372931260349;0.8590579283277371;[ALS2]
GO:0035023;regulation of Rho protein signal transduction;9.0;0.8436909121759173;0.8180860812682478;9.318369324188282;48.758993290020136;4.879233827729558;0.0016319196251719597;0.645764870037956;[ALS2]
GO:0090314;positive regulation of protein targeting to membrane;10.0;0.9326813400603323;0.8815816818910864;9.587702257971866;497.0805077511855;6.343086423195323;0.016636837251019197;0.7396267465268138;[CIB1]
GO:0070507;regulation of microtubule cytoskeleton organization;7.0;0.6073376606709605;0.6545881955926808;8.242229891372231;33.71079736555127;4.584116776790259;0.0011282700500770656;0.5853513104054853;[PDCD6IP, TPR, CIB1, PAFAH1B1]
GO:1903543;positive regulation of exosomal secretion;9.0;1.0;0.896240625180289;9.628524252492122;273.97956964224545;7.069023426578259;0.009169849630321672;0.757750811958709;[PDCD6IP]
GO:0006260;DNA replication;7.0;0.7307253602413294;0.7162820453778652;9.271849308553389;254.20053156235352;4.77312732173501;0.008507863025766288;0.5950173184638491;[NFIC]
GO:0043928;exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay;11.0;0.9326813400603323;0.8987696223598284;9.60383163990175;718.8643508040237;6.280566066213989;0.024059742885497587;0.7536173930320365;[CNOT6]
GO:0097191;extrinsic apoptotic signaling pathway;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;51.05903939735586;5.277263957350204;0.0017089000984773794;0.5929998367869052;[CASP2, CIB1]
GO:0048812;neuron projection morphogenesis;7.0;0.6547035408479693;0.6782711356811852;8.502512989635898;62.99970935475633;4.360973225476049;0.002108543576046295;0.5739397388140403;[SLC9A6, ALS2, PAFAH1B1]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[ANKRD17, UBE2I]
GO:0046633;alpha-beta T cell proliferation;7.0;0.7980440201809971;0.7499413753476991;9.420884887713877;76.83090642196836;8.67846133901236;0.0025714612946166663;0.7947362817240173;[DOCK2]
GO:0043001;Golgi to plasma membrane protein transport;8.0;0.9326813400603323;0.8413406700301662;9.589303539338841;211.1766051690936;6.481236761676141;0.00706789092840378;0.7064507494004503;[SYS1]
GO:0097190;apoptotic signaling pathway;5.0;0.6954798709641801;0.6379809473430103;8.529911963824013;23.17027026302992;4.145861845859104;7.75488093814194E-4;0.5022605794604473;[DPF2, CASP2, CIB1]
GO:0043487;regulation of RNA stability;7.0;0.6954798709641801;0.6986593007392905;9.033817144745429;143.5680863533099;4.925043363760852;0.004805094647356126;0.6027863119178691;[SMG5]
GO:0097192;extrinsic apoptotic signaling pathway in absence of ligand;7.0;1.0;0.8509193652572005;9.628524252492122;76.30875120206336;6.375876246018314;0.0025539852293156346;0.6769819729871445;[CASP2]
GO:0000398;mRNA splicing, via spliceosome;11.0;0.8259837884571596;0.845420846558242;9.4949928598676;356.66873027722005;4.19357731889877;0.011937381421361158;0.6468886914394342;[EFTUD2, CPSF2, DDX42, DDX41, SRRM1]
GO:0021895;cerebral cortex neuron differentiation;6.0;0.8259837884571596;0.7361122068187242;9.176539128749065;26.729186262933762;7.138016298065211;8.946018095145202E-4;0.6881587980249038;[PAFAH1B1]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[KARS, PTPRA]
GO:0016070;RNA metabolic process;6.0;0.38914095662452564;0.5176907909024073;6.453451050282314;112.24841944109592;1.6174128906170937;0.0037568535816745637;0.4058348830336941;[AHCYL1, CPSF2, DDX42, CNOT10, DDX41, SMG5, SRRM1, EFTUD2, ATXN2, CNOT6, KARS, CNOT1, NFIC, SAP130, DPF2, FASTKD5, INTS4, ZNF564]
GO:0031338;regulation of vesicle fusion;6.0;0.7248374789738407;0.6855390520770648;8.935377071932177;48.20117096329211;5.514393750639154;0.0016132498139038735;0.6051266654433651;[VPS18, RABGAP1, VPS41]
GO:0051660;establishment of centrosome localization;5.0;1.0;0.7902410118609202;9.628524252492122;49.27724762489731;8.390779266560578;0.0016492651313616785;0.7193458537639684;[PAFAH1B1]
GO:0051661;maintenance of centrosome location;6.0;1.0;0.8231203125901445;9.628524252492122;46.01609631687506;7.9853141584524145;0.0015401173319278046;0.7314896500084853;[PAFAH1B1]
GO:0000281;mitotic cytokinesis;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;28.615093046006976;5.649939242635378;9.577214123380678E-4;0.5791791674783379;[PDCD6IP]
GO:0010759;positive regulation of macrophage chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;998.0472698001994;7.292166977892469;0.033403743935984914;0.7881627702307852;[KARS]
GO:0048387;negative regulation of retinoic acid receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;187.41437209568753;7.57984905034425;0.006272590372058239;0.738553198190834;[CNOT1]
GO:2000256;positive regulation of male germ cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;233.06462971964467;9.777073627680469;0.007800463412167529;0.8509193652572005;[CIB1]
GO:0031453;positive regulation of heterochromatin assembly;11.0;0.8933024483968273;0.8790801765280758;9.533214072687796;211.66154632466885;9.083926447120524;0.007084121472462179;0.8969813732811862;[TPR]
GO:0016197;endosomal transport;5.0;0.7090535922965819;0.6447678080092112;8.817594036275793;47.18803257139101;4.463867648638682;0.0015793409836922997;0.5185234110033771;[ALS2]
GO:2000377;regulation of reactive oxygen species metabolic process;5.0;0.660418147677249;0.6204500856995447;8.475844742553736;26.78229071161683;4.7018998124466425;8.963791676210415E-4;0.5306963869301438;[AATF, PARL]
GO:0070863;positive regulation of protein exit from endoplasmic reticulum;9.0;0.9326813400603323;0.8625812952104552;9.582004236857228;386.41577867641314;7.212124270218933;0.012932988360676686;0.7650689957573628;[TMEM30A]
GO:0036109;alpha-linolenic acid metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;214.3732045654151;7.212124270218933;0.0071748782334459795;0.7650689957573628;[FADS1]
GO:0033630;positive regulation of cell adhesion mediated by integrin;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;34.61675044652454;6.943860283624253;0.0011585914843924019;0.6453503496879909;[CIB1]
GO:0098719;sodium ion import across plasma membrane;9.0;1.0;0.896240625180289;9.628524252492122;255.84958837647977;7.069023426578259;0.008563055473280314;0.757750811958709;[SLC9A6]
GO:0019226;transmission of nerve impulse;4.0;1.0;0.75;9.628524252492122;26.01624213687652;6.943860283624253;8.70740211223441E-4;0.6051093378270707;[PAFAH1B1]
GO:1903553;positive regulation of extracellular exosome assembly;8.0;1.0;0.875;9.628524252492122;166.66584496590895;8.390779266560578;0.005578155841486647;0.8041048419030481;[PDCD6IP]
GO:0035493;SNARE complex assembly;6.0;1.0;0.8231203125901445;9.628524252492122;44.51706700895919;7.8311634786251565;0.0014899461700306506;0.7236063770733796;[VAMP4]
GO:0006398;mRNA 3'-end processing by stem-loop binding and cleavage;10.0;1.0;0.9152410118609203;9.628524252492122;473.82980460404525;8.16763571524637;0.015858657140958726;0.8329342821725234;[CPSF2]
GO:0000724;double-strand break repair via homologous recombination;9.0;0.8653626801206646;0.8289219652406215;9.515195567185119;520.6240308586224;5.299736813202263;0.01742481778162994;0.6672694122704188;[WDR48]
GO:0042045;epithelial fluid transport;5.0;0.8933024483968273;0.736892236059334;9.34084218004034;24.0554433753243;7.697632086000634;8.051140412786058E-4;0.6838982747154925;[AHCYL1]
GO:0007004;telomere maintenance via telomerase;9.0;1.0;0.896240625180289;9.628524252492122;760.4775577437022;6.686031174322154;0.025452499472313803;0.7381645703673706;[SMG5]
GO:0008333;endosome to lysosome transport;6.0;0.8436909121759173;0.7449657686781032;9.36615998802463;62.67584315854233;5.769740442447999;0.0020977040659196657;0.618185107137305;[VPS18, VPS41]
GO:0006275;regulation of DNA replication;7.0;0.6144040707577935;0.6581214006360973;8.623002386890024;150.73814970462044;5.142344639450834;0.005045070215086414;0.6138991092621975;[ANKRD17]
GO:1904886;beta-catenin destruction complex disassembly;5.0;1.0;0.7902410118609202;9.628524252492122;38.04764185170599;6.7325511899570465;0.0012734203321220245;0.6345439928109722;[DVL3]
GO:0000963;mitochondrial RNA processing;8.0;0.7140352122741334;0.7320176061370667;9.205667401672088;248.66574563202212;7.004484905440688;0.008322618721662041;0.7332096838060964;[FASTKD5]
GO:0006397;mRNA processing;8.0;0.7140352122741334;0.7320176061370667;9.165900730544008;234.3529203123214;3.6745150330669007;0.00784358133891816;0.5629148696734654;[EFTUD2, AHCYL1, CPSF2, DDX42, FASTKD5, DDX41, SRRM1]
GO:0009306;protein secretion;8.0;0.5696777571895439;0.659838878594772;7.923776160253697;130.2874189859313;4.786641040901733;0.004360602662394617;0.6197890454332871;[PAFAH1B1]
GO:0000289;nuclear-transcribed mRNA poly(A) tail shortening;10.0;0.9326813400603323;0.8815816818910864;9.603206444507832;717.2549128915896;6.686031174322154;0.0240058764469685;0.7571649570480019;[CNOT6, CNOT1, CNOT10]
GO:0000288;nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay;10.0;1.0;0.9152410118609203;9.628524252492122;717.2549128915896;7.292166977892469;0.0240058764469685;0.7881627702307852;[CNOT1]
GO:0016180;snRNA processing;9.0;0.7980440201809971;0.7952626352707877;9.354087406790361;356.38664419027253;6.221725566191056;0.01192794025389202;0.7144199599751273;[INTS4]
GO:0071260;cellular response to mechanical stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;56.1235610070294;5.420364800990877;0.00187840507897962;0.5674387198563348;[CASP2]
GO:0044351;macropinocytosis;7.0;0.8653626801206646;0.7836007053175329;9.405380701177911;29.536082298666074;7.8311634786251565;9.88546093788053E-4;0.7514054297404357;[DOCK2]
GO:0010765;positive regulation of sodium ion transport;8.0;0.7586651285174919;0.754332564258746;9.0306872517365;68.46428617144959;6.375876246018314;0.0022914380443011736;0.701062607729944;[AHCYL1]
GO:0031440;regulation of mRNA 3'-end processing;9.0;0.811012628672052;0.801746939516315;9.434368238051164;93.36161366264447;6.686031174322154;0.003124729189291454;0.7381645703673706;[AHCYL1]
GO:0032412;regulation of ion transmembrane transporter activity;7.0;0.5374962537808747;0.6196674921476379;7.763739648249177;60.98082996678185;4.347727998726029;0.0020409734998042767;0.5732623773020782;[AHCYL1]
GO:1905050;positive regulation of metallopeptidase activity;10.0;0.8933024483968273;0.861892236059334;9.59573442966913;498.63588947967594;7.8311634786251565;0.016688894477719096;0.8157270763441555;[KARS]
GO:2001235;positive regulation of apoptotic signaling pathway;8.0;0.6997970393407541;0.724898519670377;9.176539128749065;291.4603159253591;4.6590798152637145;0.009754914476767216;0.6132655584219551;[CASP2]
GO:0035249;synaptic transmission, glutamatergic;8.0;1.0;0.875;9.628524252492122;25.73829654599903;6.444869117505266;8.61437622431563E-4;0.7045909063862833;[ALS2]
GO:0007173;epidermal growth factor receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.040737587590003;32.38857880465376;5.788089581116195;0.0010840165847632744;0.6922437955322635;[CAMLG]
GO:0006886;intracellular protein transport;8.0;0.5537205960740763;0.6518602980370382;8.117066748418225;90.55259897265384;3.0436717358431102;0.0030307139955665606;0.5306535141162272;[PEX16, VPS18, AHCYL1, RABGAP1, PEX19, VPS41, TMED2, TNPO2, SEC24C, ARCN1]
GO:1904816;positive regulation of protein localization to chromosome, telomeric region;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;74.11254383842964;7.292166977892469;0.002480480145313119;0.7238411236270654;[GNL3L]
GO:0043666;regulation of phosphoprotein phosphatase activity;9.0;0.7436939687323844;0.7680876095464813;9.328419660041783;158.30216566976694;5.058574756385375;0.005298231022267458;0.6549363734696205;[PPP1R7]
GO:0006887;exocytosis;6.0;0.6696747006330769;0.657957662906683;8.375761283996754;37.082880499217325;3.1596706497059923;0.0012411306378830758;0.4847060165558207;[TMEM30A, PSMB1, VPS41, VAMP4, DOCK2]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[RIC8A, RABGAP1, ALS2, DVL3, DOCK2]
GO:0006636;unsaturated fatty acid biosynthetic process;9.0;0.7508913569872202;0.7716863036738992;9.34084218004034;458.36729553176707;6.343086423195323;0.01534114087766428;0.7206263598461826;[FADS1]
GO:0006999;nuclear pore organization;5.0;0.8933024483968273;0.736892236059334;9.4949928598676;38.430292282043744;7.069023426578259;0.0012862272976623997;0.6517511986393402;[TPR]
GO:0032929;negative regulation of superoxide anion generation;8.0;1.0;0.875;9.628524252492122;144.98455126321716;8.67846133901236;0.004852502453155066;0.8188169164668168;[AATF]
GO:0045055;regulated exocytosis;7.0;0.6873818243518346;0.6946102774331178;8.567652291806858;38.46917486033492;3.2638435167681625;0.0012875286625657566;0.5178324744889699;[TMEM30A, PSMB1, VPS41, DOCK2]
GO:2000036;regulation of stem cell population maintenance;4.0;0.7369933605727446;0.6184966802863723;9.040737587590003;23.085677266902636;6.518977089658987;7.726568423625676E-4;0.5833807915285978;[CNOT1]
GO:0051607;defense response to virus;6.0;0.8653626801206646;0.7558016526504768;9.485423408851448;78.89111305633469;4.573066940603674;0.0026404145566033123;0.5569871686019774;[DDX41]
GO:0071577;zinc ion transmembrane transport;9.0;0.8259837884571596;0.8092325194088689;9.35659053700848;134.4975615453565;6.599019797332524;0.00450151234497627;0.7337148045016781;[SLC30A7]
GO:0031397;negative regulation of protein ubiquitination;10.0;0.7508913569872202;0.7906866903545304;9.372590878354922;529.4632463014641;5.572381008289503;0.01772065836772442;0.7002128357670632;[GNL3L]
GO:0006094;gluconeogenesis;7.0;1.0;0.8509193652572005;9.628524252492122;174.6088252776196;5.926926025970411;0.005844000244301424;0.6540226378555745;[TPI1]
GO:0016558;protein import into peroxisome matrix;11.0;1.0;0.9324289523296623;9.628524252492122;631.8486156540207;7.474488534686424;0.021147404539104363;0.8146746435927894;[PEX16]
GO:0046827;positive regulation of protein export from nucleus;9.0;0.811012628672052;0.801746939516315;9.431813958246067;516.7269860224134;6.7325511899570465;0.017294387198074676;0.740543606130341;[TPR]
GO:0008033;tRNA processing;9.0;0.6007507099811141;0.6966159801708461;8.495425787752843;356.94625997820395;4.973052582947213;0.011946670090692574;0.6505627655428052;[KARS]
GO:0035195;gene silencing by miRNA;10.0;1.0;0.9152410118609203;9.628524252492122;181.23087468718478;7.379178354882098;0.006065634278582023;0.7926125360964777;[CNOT6, CNOT1]
GO:1901673;regulation of mitotic spindle assembly;10.0;1.0;0.9152410118609203;9.628524252492122;218.77880646863287;6.832634648514029;0.0073223297643623805;0.7646622655359331;[TPR]
GO:0032481;positive regulation of type I interferon production;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;65.23665507211369;5.618190544320798;0.002183412136085803;0.610434838299289;[DDX41]
GO:0061088;regulation of sequestering of zinc ion;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;37.41913998203334;7.474488534686424;0.001252384940159041;0.7053660038532718;[SLC30A7]
GO:0042220;response to cocaine;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;106.24722930474235;6.343086423195323;0.0035559991485312878;0.647506047256038;[EFTUD2]
GO:0048205;COPI coating of Golgi vesicle;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;22.707504301080803;7.9853141584524145;7.599997335300838E-4;0.7592887026755414;[TMED2]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[TMEM30A, PSMB1, DOCK2]
GO:0006897;endocytosis;5.0;0.6324783794010864;0.6064802015614634;8.088079211544972;26.35802846831835;3.582668236575797;8.821794921490709E-4;0.47345883209051776;[FNBP1, DOCK2]
GO:0006414;translational elongation;6.0;0.7671156992804218;0.7066781622303554;9.117698628726131;105.15840431616243;4.981283082083729;0.0035195571560423886;0.5778633610612594;[EFTUD2]
GO:0006895;Golgi to endosome transport;7.0;1.0;0.8509193652572005;9.628524252492122;52.5351401021073;6.8867018697843045;0.0017583038606610233;0.7031056191423581;[SYS1]
GO:1902525;regulation of protein monoubiquitination;10.0;0.8933024483968273;0.861892236059334;9.4949928598676;79.97782052321757;8.16763571524637;0.0026767856775466578;0.8329342821725234;[WDR48]
GO:0001881;receptor recycling;6.0;0.8436909121759173;0.7449657686781032;9.223059144383958;34.80127764040325;7.379178354882098;0.0011647674435078296;0.7004918368257019;[CAMLG, ALS2]
GO:0048208;COPII vesicle coating;6.0;1.0;0.8231203125901445;9.628524252492122;62.43707956725794;5.6339389012889365;0.0020897128633926582;0.6112402100070131;[TMED2, SEC24C]
GO:0006406;mRNA export from nucleus;9.0;0.8933024483968273;0.8428918493787028;9.523163736834295;121.36021434248079;5.132682728539097;0.004061817156940898;0.658726258611935;[TPR, CPSF2, SMG5, SRRM1]
GO:0033209;tumor necrosis factor-mediated signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;30.19135422731818;5.395046993006588;0.00101047745553359;0.6268223193749;[KARS]
GO:0006404;RNA import into nucleus;8.0;0.8933024483968273;0.8216512241984136;9.510741216835738;77.77267148825172;8.67846133901236;0.002602981323851637;0.8188169164668168;[TPR]
GO:0006888;ER to Golgi vesicle-mediated transport;6.0;1.0;0.8231203125901445;9.628524252492122;49.13394272044514;4.493869898942481;0.001644468845175705;0.5529370282083849;[DCTN5, GOLGB1, TMED2, SEC24C, ARCN1]
GO:0015917;aminophospholipid transport;8.0;1.0;0.875;9.628524252492122;83.80687118295802;8.390779266560578;0.0028049405572063047;0.8041048419030481;[TMEM30A]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[UBE2I]
GO:0031023;microtubule organizing center organization;3.0;0.7307253602413294;0.5634829927108093;8.465373442686442;24.42168715513283;5.459585514144159;8.173718909907947E-4;0.47732376968016754;[PAFAH1B1]
GO:0050766;positive regulation of phagocytosis;8.0;0.7671156992804218;0.7585578496402109;9.34084218004034;175.32691305650852;5.825829909099042;0.005868033996023792;0.6729332124801218;[DOCK2]
GO:0072659;protein localization to plasma membrane;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.42666064804821;4.677207199856271;0.002189771451718415;0.5623129063031725;[SYS1, TMED2]
GO:0016567;protein ubiquitination;9.0;0.6913464685778243;0.7419138594692012;8.996001693748612;153.79381005389072;3.300101264790787;0.005147340417060716;0.5650079573320931;[UBE2I, HERC1, KCTD10, ZFP91]
GO:0090307;mitotic spindle assembly;8.0;1.0;0.875;9.628524252492122;186.05212215721153;6.193554689224359;0.006226997092562797;0.6917386748366816;[TUBGCP2]
GO:0046718;viral entry into host cell;7.0;0.7671156992804218;0.7344772148974115;8.935377071932177;28.374411874040543;5.346256828837156;9.496660301113433E-4;0.6243271881103005;[VPS18]
GO:0036035;osteoclast development;5.0;1.0;0.7902410118609202;9.628524252492122;66.38585475831493;7.9853141584524145;0.0022218748153703875;0.6986103492792611;[PAFAH1B1]
GO:0007032;endosome organization;5.0;0.8436909121759173;0.712086467948879;9.223059144383958;20.915744831851537;5.528578385631111;7.000311565738116E-4;0.5729727676072827;[VPS18, PDCD6IP, ALS2, VPS33B]
GO:0090630;activation of GTPase activity;7.0;1.0;0.8509193652572005;9.628524252492122;49.337455126924546;5.2552850506314295;0.0016512802222712962;0.6196748871422394;[RABGAP1]
GO:0046832;negative regulation of RNA export from nucleus;8.0;0.8436909121759173;0.7968454560879586;9.446202695698167;195.26423809717332;9.083926447120524;0.006535318322707228;0.839552420951524;[TPR]
GO:0090073;positive regulation of protein homodimerization activity;6.0;1.0;0.8231203125901445;9.628524252492122;47.416497719221994;7.57984905034425;0.0015869875065849188;0.710754145523778;[GNL3L]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[PSMB1]
GO:0006623;protein targeting to vacuole;10.0;0.8436909121759173;0.837086467948879;9.548481544818586;198.71733053910478;6.343086423195323;0.006650890219157237;0.7396267465268138;[VPS41]
GO:0001961;positive regulation of cytokine-mediated signaling pathway;7.0;0.7192862368539868;0.710562483684194;8.965230035081857;244.22079422365863;5.948432231191374;0.008173850198220667;0.6551224661907153;[PAFAH1B1]
GO:0006855;drug transmembrane transport;5.0;0.5781283279524737;0.5793051758371571;7.293149336675085;29.084245973375534;5.407625775213448;9.73423538606871E-4;0.5667872454856517;[TMEM30A]
GO:0006977;DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest;11.0;1.0;0.9324289523296623;9.628524252492122;888.119660647831;5.75172193694532;0.0297245657860804;0.7265722796674696;[CNOT6, CNOT1, CASP2, CNOT10]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[PAFAH1B1]
GO:0045199;maintenance of epithelial cell apical/basal polarity;6.0;1.0;0.8231203125901445;9.628524252492122;34.60247581110787;7.138016298065211;0.001158113725191344;0.6881587980249038;[PDCD6IP]
GO:0072321;chaperone-mediated protein transport;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;57.348299591639034;7.474488534686424;0.0019193959772133386;0.7572456912631272;[PEX19]
GO:0046166;glyceraldehyde-3-phosphate biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;293.39227460770104;9.083926447120524;0.009819575395215269;0.7876727335416686;[TPI1]
GO:0047496;vesicle transport along microtubule;8.0;0.7866048967936545;0.7683024483968273;9.36615998802463;173.0068769504478;6.039404009397101;0.005790384475450878;0.6838554019015759;[PAFAH1B1]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[CIB1]
GO:0050658;RNA transport;7.0;0.6393367784920305;0.6705877545032157;8.391761625343195;40.09103529276204;4.488806596985934;0.0013418108716594672;0.5804771433779154;[ATXN2, TPR, CPSF2, SMG5, SRRM1]
GO:0060693;regulation of branching involved in salivary gland morphogenesis;6.0;0.8653626801206646;0.7558016526504768;9.36615998802463;93.99544391330774;7.697632086000634;0.0031459429173709623;0.7167775754447168;[BTBD7]
GO:0007281;germ cell development;4.0;0.8653626801206646;0.6826813400603323;9.34084218004034;71.68419734523428;4.759793790865545;0.0023992055735558276;0.4934160758179115;[CIB1, PAFAH1B1]
GO:0007286;spermatid development;5.0;1.0;0.7902410118609202;9.628524252492122;72.7828096339012;5.370354380416217;0.0024359751381706407;0.5648811846224242;[CIB1]
GO:1903078;positive regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.434368238051164;218.50214452761784;5.845247994956144;0.00731307013817619;0.6739262542938873;[CIB1]
GO:0030162;regulation of proteolysis;6.0;0.5083192675395742;0.5772799463599316;7.4738592895746985;43.97722126997476;3.092461900012542;0.001471878018976464;0.48126895797097113;[KBTBD4, WDR48, KARS, PARL]
GO:1900245;positive regulation of MDA-5 signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;756.7335043639653;8.390779266560578;0.02532718937512329;0.8253454670833372;[ANKRD17]
GO:1903755;positive regulation of SUMO transferase activity;11.0;1.0;0.9324289523296623;9.628524252492122;655.8514403923152;9.777073627680469;0.021950757481955283;0.9324289523296623;[UBE2I]
GO:1900246;positive regulation of RIG-I signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;756.7335043639653;7.8311634786251565;0.02532718937512329;0.7967266896635242;[ANKRD17]
GO:0060213;positive regulation of nuclear-transcribed mRNA poly(A) tail shortening;11.0;1.0;0.9324289523296623;9.628524252492122;968.1421379136862;7.379178354882098;0.03240284608461468;0.8098004765652196;[CNOT1]
GO:0002276;basophil activation involved in immune response;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;82.20461051260416;9.083926447120524;0.002751314334510546;0.8154717862087246;[KARS]
GO:0051081;nuclear envelope disassembly;5.0;0.8259837884571596;0.7032329060895001;9.223059144383958;57.485999778575895;7.004484905440688;0.0019240046785479927;0.6484506956670166;[PAFAH1B1]
GO:0002277;myeloid dendritic cell activation involved in immune response;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;81.79914540449643;8.67846133901236;0.0027377437822370863;0.7669372290569613;[DOCK2]
GO:0070371;ERK1 and ERK2 cascade;10.0;1.0;0.9152410118609203;9.628524252492122;233.3964595037646;6.481236761676141;0.007811569456414605;0.7466917612613706;[KARS]
GO:0090090;negative regulation of canonical Wnt signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.283683766200392;236.99226377157444;4.932886541221878;0.00793191778924446;0.6272680471207706;[DVL3]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[ANKRD17]
GO:0097711;ciliary basal body-plasma membrane docking;5.0;1.0;0.7902410118609202;9.628524252492122;21.38880323109876;5.223196736079928;7.158639954716971E-4;0.5573555358475362;[PAFAH1B1]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[KARS, CIB1]
GO:0031124;mRNA 3'-end processing;9.0;0.8436909121759173;0.8180860812682478;9.52844079393514;355.1646528804444;5.407625775213448;0.011887041304472852;0.6727868588050205;[AHCYL1, CPSF2, SRRM1]
GO:0032210;regulation of telomere maintenance via telomerase;9.0;0.8933024483968273;0.8428918493787028;9.541512875502493;259.9597501127497;5.8067817141283475;0.00870061888768786;0.693199712083778;[GNL3L, SMG5]
GO:0031122;cytoplasmic microtubule organization;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;50.45034613020222;5.734022359845919;0.0016885276826141221;0.6163584827319739;[TUBGCP2, CIB1, PAFAH1B1]
GO:0032211;negative regulation of telomere maintenance via telomerase;10.0;1.0;0.9152410118609203;9.628524252492122;1705.737369485817;6.781341354126479;0.05708949469272255;0.7620391240755716;[GNL3L]
GO:0071901;negative regulation of protein serine/threonine kinase activity;11.0;0.7369933605727446;0.8009256326160346;9.385578073881732;1262.8536775520981;4.8942717050940985;0.0422665760931464;0.6827222349350845;[CIB1]
GO:0036258;multivesicular body assembly;7.0;1.0;0.8509193652572005;9.628524252492122;62.72328125453724;6.375876246018314;0.0020992917763011008;0.6769819729871445;[PDCD6IP]
GO:0071902;positive regulation of protein serine/threonine kinase activity;11.0;0.6763753087927167;0.7706166067260205;9.206529842432747;1260.5827351979337;3.9422628906178643;0.04219056969626795;0.6340364598898325;[KARS, ALS2, DVL3, CIB1]
GO:0030036;actin cytoskeleton organization;5.0;0.6347111282356054;0.607596575978723;8.048073876931273;29.6146440060229;3.9779809732199434;9.911754834323397E-4;0.49367514382642164;[PDCD6IP, DOCK2, PAFAH1B1]
GO:0007094;mitotic spindle assembly checkpoint;13.0;1.0;0.9625549647676366;9.628524252492122;1801.8011146821202;6.781341354126479;0.060304661792685066;0.8093530769822879;[TPR]
GO:0043507;positive regulation of JUN kinase activity;13.0;0.8653626801206646;0.8952363048279688;9.582714716460828;4931.413721535565;5.459585514144159;0.16504997927558432;0.7417584218576596;[DVL3]
GO:0090611;ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway;7.0;1.0;0.8509193652572005;9.628524252492122;51.84712944745551;8.16763571524637;0.001735276763219217;0.7686126355688037;[PDCD6IP]
GO:0090179;planar cell polarity pathway involved in neural tube closure;10.0;1.0;0.9152410118609203;9.628524252492122;275.5135961891709;7.212124270218933;0.009221192118313007;0.7840693824379941;[DVL3]
GO:1903003;positive regulation of protein deubiquitination;10.0;0.8653626801206646;0.8479223519212526;9.5544162803384;912.3518242519174;7.8311634786251565;0.030535594494377795;0.8157270763441555;[WDR48]
GO:0016925;protein sumoylation;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;311.84626772129184;6.250713103064308;0.010437213937211602;0.7159023839588838;[UBE2I, SUMO3]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[PEX16, VPS18, AHCYL1, SYS1, PDCD6IP, RABGAP1, PEX19, VPS33B, ARCN1, VPS41, TMED2, TNPO2, SEC24C, PAFAH1B1]
GO:0007097;nuclear migration;5.0;0.7140352122741334;0.6472586179979869;8.712233520617966;66.0178211805495;6.781341354126479;0.002209557062731295;0.6370391240755715;[PAFAH1B1]
GO:0090176;microtubule cytoskeleton organization involved in establishment of planar polarity;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;33.1981629444775;8.67846133901236;0.0011111126373447525;0.7669372290569613;[PAFAH1B1]
GO:0038031;non-canonical Wnt signaling pathway via JNK cascade;10.0;1.0;0.9152410118609203;9.628524252492122;33.206889128170424;8.16763571524637;0.001111404694859899;0.8329342821725234;[DVL3]
GO:0046456;icosanoid biosynthetic process;7.0;0.7586651285174919;0.7302519295159464;9.34084218004034;261.7716400169668;6.113511981550823;0.008761261212186958;0.663564652301091;[FADS1]
GO:0090050;positive regulation of cell migration involved in sprouting angiogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;645.2358217485536;6.7325511899570465;0.021595462279385098;0.7767319332797141;[CIB1]
GO:0043622;cortical microtubule organization;7.0;1.0;0.8509193652572005;9.628524252492122;73.4832728317158;8.390779266560578;0.0024594190110255446;0.7800242071602487;[PAFAH1B1]
GO:0042776;mitochondrial ATP synthesis coupled proton transport;13.0;1.0;0.9625549647676366;9.628524252492122;10144.915177257948;6.943860283624253;0.3395411811519228;0.8176643025947071;[COX5B]
GO:0097484;dendrite extension;5.0;1.0;0.7902410118609202;9.628524252492122;51.99108915072818;7.474488534686424;0.0017400949649324319;0.6724867031240476;[SLC9A6]
GO:0030307;positive regulation of cell growth;6.0;0.6954798709641801;0.6708602480722345;8.712233520617966;80.64681300048527;4.733648510761223;0.0026991762537066665;0.5651993175676412;[CIB1, PAFAH1B1]
GO:0007409;axonogenesis;8.0;0.6873818243518346;0.7186909121759173;8.667113085337498;64.60914726719044;4.956792062075433;0.0021624100145753813;0.6284905765689417;[ALS2, PAFAH1B1]
GO:0031990;mRNA export from nucleus in response to heat stress;10.0;1.0;0.9152410118609203;9.628524252492122;173.8710648133593;9.083926447120524;0.005819308065503943;0.8797934328124444;[TPR]
GO:0016255;attachment of GPI anchor to protein;7.0;1.0;0.8509193652572005;9.628524252492122;151.15475272427284;7.9853141584524145;0.005059013543235805;0.7592887026755414;[PIGS]
GO:0019886;antigen processing and presentation of exogenous peptide antigen via MHC class II;5.0;1.0;0.7902410118609202;9.628524252492122;42.20009821028515;5.192106149009898;0.0014123993094755708;0.5557655617789146;[DCTN5, SEC24C]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[CNOT6, KARS, ALS2, PTPRA, CNOT1, DVL3, CASP2, CNOT10, DOCK2]
GO:0010499;proteasomal ubiquitin-independent protein catabolic process;8.0;1.0;0.875;9.628524252492122;190.80819184730524;6.518977089658987;0.006386178464905405;0.7083807915285978;[PSMB1]
GO:0090503;RNA phosphodiester bond hydrolysis, exonucleolytic;8.0;0.8436909121759173;0.7968454560879586;9.466005322994347;231.13671471601307;6.166155715036245;0.007735937832006836;0.6903374900225189;[CNOT6, CNOT1]
GO:1905793;protein localization to pericentriolar material;10.0;1.0;0.9152410118609203;9.628524252492122;37.378778991281564;9.083926447120524;0.0012510340941211122;0.8797934328124444;[GOLGB1]
GO:0042307;positive regulation of protein import into nucleus;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;778.7460608588023;6.063501560976162;0.02606392983099081;0.706328376990269;[TPR]
GO:0090501;RNA phosphodiester bond hydrolysis;7.0;0.6369964171292115;0.6694175738218062;8.663443356448536;229.5272768035792;4.7664383335842135;0.007682071393477758;0.5946752432987477;[CNOT6, CNOT1, CPSF2, SMG5]
GO:0021702;cerebellar Purkinje cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;49.9926366230673;7.57984905034425;0.0016732085573221292;0.710754145523778;[HERC1]
GO:0002091;negative regulation of receptor internalization;9.0;0.9326813400603323;0.8625812952104552;9.585964638073326;394.0818765588627;7.57984905034425;0.013189565757762102;0.7838744581139225;[ATXN2]
GO:1902600;proton transmembrane transport;8.0;0.7586651285174919;0.754332564258746;9.117698628726131;95.86613314633948;4.835431205071165;0.0032085532024895276;0.6222841766978864;[SLC9A6, COX5B]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[PDCD6IP, KCTD10]
GO:0046469;platelet activating factor metabolic process;7.0;0.9326813400603323;0.8172600352873667;9.574457031221845;206.08016991717045;7.9853141584524145;0.0068973178270158595;0.7592887026755414;[PAFAH1B1]
GO:0008630;intrinsic apoptotic signaling pathway in response to DNA damage;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;84.23129647150353;5.54296712308321;0.002819145689655962;0.6343869617060081;[CASP2]
GO:0000226;microtubule cytoskeleton organization;5.0;0.579397892394798;0.5799399580583193;7.662411396119289;30.307791186580253;3.8212362582156385;0.0010143744957736317;0.4856592118117268;[TUBGCP2, CIB1, VAMP4, PAFAH1B1]
GO:0045931;positive regulation of mitotic cell cycle;6.0;0.6073376606709605;0.6267891429256247;8.04155919591008;60.92102604112766;4.779861353916354;0.0020389719162326697;0.5675626445157116;[ANKRD17, TPR, PAFAH1B1]
GO:0001675;acrosome assembly;6.0;1.0;0.8231203125901445;9.628524252492122;135.95286722949908;7.138016298065211;0.004550220116534439;0.6881587980249038;[PAFAH1B1]
GO:0010824;regulation of centrosome duplication;9.0;0.7866048967936545;0.7895430735771163;9.474373572664863;54.56804827344474;6.063501560976162;0.0018263434676571142;0.706328376990269;[PDCD6IP]
GO:0016485;protein processing;6.0;0.6519675769143192;0.6491041010473041;8.320191432841943;99.81063536400724;4.720827822332161;0.0033405721418933456;0.564543666965156;[CASP2]
GO:0035307;positive regulation of protein dephosphorylation;9.0;0.811012628672052;0.801746939516315;9.464221201200845;660.9024749708963;6.063501560976162;0.022119811063664396;0.706328376990269;[PPP1R7]
GO:0035303;regulation of dephosphorylation;7.0;0.620063164412167;0.660950947463284;8.242229891372231;31.28210038194581;4.458953633836253;0.001046983747721169;0.5789504614541361;[PPP1R7, SMG5]
GO:0010389;regulation of G2/M transition of mitotic cell cycle;8.0;0.7369933605727446;0.7434966802863723;8.986670366319727;58.92720908338202;4.74012102526684;0.001972240656975688;0.6174100096703167;[PAFAH1B1]
GO:0007193;adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.117698628726131;28.36322711391944;5.334422371190153;9.492916862557204E-4;0.6478026081386739;[RIC8A]
GO:0035542;regulation of SNARE complex assembly;7.0;0.8933024483968273;0.7975705894556142;9.474373572664863;81.00006219528554;7.474488534686424;0.0027109991863529964;0.7331650565203278;[VPS18, VPS41]
GO:0045947;negative regulation of translational initiation;9.0;0.7508913569872202;0.7716863036738992;9.377209824211215;1335.4538949630598;6.832634648514029;0.044696440033937586;0.7456618788553018;[TPR]
GO:0008286;insulin receptor signaling pathway;8.0;0.8653626801206646;0.8076813400603323;9.34084218004034;31.002284443533863;5.346256828837156;0.0010376185600805164;0.6484078228531001;[PTPRA]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[KARS, CIB1]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[CNOT6, WDR48, CIB1]
GO:0051151;negative regulation of smooth muscle cell differentiation;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;145.64858387880895;7.069023426578259;0.004874727027208368;0.7124295520356204;[ANKRD17]
GO:0042795;snRNA transcription by RNA polymerase II;12.0;1.0;0.9481203125901445;9.628524252492122;1410.6487555617684;5.528578385631111;0.047213144347195396;0.730852068336507;[INTS4]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[NFIC, DPF2, DDX41, AATF, ZNF564]
GO:0040019;positive regulation of embryonic development;6.0;0.622025257344104;0.6341329412621965;8.059908334578276;86.83381305781886;6.250713103064308;0.0029062495776870714;0.6427820713687392;[PAFAH1B1]
GO:0043525;positive regulation of neuron apoptotic process;8.0;0.8436909121759173;0.7968454560879586;9.392135474427892;179.36331192335928;5.885253329569843;0.0060031286335741505;0.6759721289664703;[CASP2]
GO:0006302;double-strand break repair;8.0;0.7586651285174919;0.754332564258746;9.318369324188282;183.0506323445446;4.689477292448085;0.006126539929698291;0.6148200868187911;[WDR48, CIB1]
GO:0001893;maternal placenta development;4.0;1.0;0.75;9.628524252492122;43.252245699280884;7.379178354882098;0.001447613739060994;0.6273715242355574;[TMED2]
GO:0006417;regulation of translation;7.0;0.5221699919663294;0.6120043612403652;8.01908634005802;212.8215771898108;3.9901762463137618;0.007122946661558481;0.554977164055858;[ATXN2, CNOT6, CNOT1, TPR, CNOT10, EIF4E2]
GO:0001766;membrane raft polarization;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;30.900032201834875;7.697632086000634;0.0010341962695718944;0.7167775754447168;[DOCK2]
GO:0051386;regulation of neurotrophin TRK receptor signaling pathway;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;67.94038154209638;7.379178354882098;0.002273903427840277;0.7004918368257019;[SLC9A6]
GO:0072520;seminiferous tubule development;4.0;1.0;0.75;9.628524252492122;49.55861996907746;7.379178354882098;0.0016586824105027187;0.6273715242355574;[WDR48]
GO:0033234;negative regulation of protein sumoylation;10.0;0.9326813400603323;0.8815816818910864;9.587702257971866;528.6159484410776;7.379178354882098;0.017692300070855854;0.7926125360964777;[GNL3L]
GO:0016236;macroautophagy;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;39.83166466328102;5.244474134527214;0.0013331299701091492;0.5584436629936305;[C6orf106]
GO:0016579;protein deubiquitination;9.0;0.7307253602413294;0.7616033053009538;9.151600180401813;202.59641706362558;4.174954806800768;0.0067807197541817285;0.6097480081553338;[WDR48, PSMB1]
GO:0033353;S-adenosylmethionine cycle;11.0;1.0;0.9324289523296623;9.628524252492122;1057.5567843103158;8.390779266560578;0.03539547383155254;0.8615337942327104;[AHCYL1]
GO:0043651;linoleic acid metabolic process;9.0;1.0;0.896240625180289;9.628524252492122;192.24999652429597;6.943860283624253;0.006434434369904319;0.7513499630073597;[FADS1]
GO:0009267;cellular response to starvation;6.0;0.6369964171292115;0.6416185211547503;8.460919092337061;112.76702064936369;4.807260328104469;0.0037742106974044997;0.5689638293298743;[FADS1]
GO:0006430;lysyl-tRNA aminoacylation;11.0;0.9326813400603323;0.8987696223598284;9.590783924509275;205.4345073903719;9.777073627680469;0.006875708083302461;0.9324289523296623;[KARS]
GO:0061621;canonical glycolysis;15.0;1.0;0.9883613244510648;9.628524252492122;17318.20443184688;6.558197802812269;0.5796247169618144;0.8237478650742711;[TPI1]
GO:0001662;behavioral fear response;5.0;1.0;0.7902410118609202;9.628524252492122;37.889479621082295;6.375876246018314;0.0012681267845998157;0.6163036195908642;[ALS2]
GO:0002741;positive regulation of cytokine secretion involved in immune response;10.0;1.0;0.9152410118609203;9.628524252492122;980.5172466015069;7.9853141584524145;0.03281702983552129;0.8236103492792612;[KARS]
GO:1903827;regulation of cellular protein localization;5.0;0.4816167172285496;0.5310493704751951;6.85593553025234;25.722958397114;3.605373030269554;8.609242683918189E-4;0.47461995629589737;[GNL3L, TMEM30A, TPR, DVL3, CIB1, PARL]
GO:0051036;regulation of endosome size;5.0;0.8653626801206646;0.7229223519212526;9.405380701177911;28.02071028012121;8.16763571524637;9.378279560736312E-4;0.7079342821725234;[ALS2]
GO:0048675;axon extension;5.0;0.8933024483968273;0.736892236059334;9.427853557029971;51.99108915072818;6.221725566191056;0.0017400949649324319;0.6084203466557585;[SLC9A6]
GO:0045046;protein import into peroxisome membrane;11.0;1.0;0.9324289523296623;9.628524252492122;483.1421344216107;7.9853141584524145;0.01617033243939992;0.8407982897480031;[PEX16, PEX19]
GO:0031047;gene silencing by RNA;8.0;0.7671156992804218;0.7585578496402109;9.168991923113682;70.59795582467933;5.885253329569843;0.002362850047416754;0.6759721289664703;[CNOT6, CNOT1, CNOT10]
GO:0016601;Rac protein signal transduction;8.0;1.0;0.875;9.628524252492122;29.60642063139588;6.7325511899570465;9.9090025448413E-4;0.719302980950052;[ALS2]
GO:0006123;mitochondrial electron transport, cytochrome c to oxygen;8.0;1.0;0.875;9.628524252492122;66.39695928536078;6.943860283624253;0.0022222464738971865;0.7301093378270707;[COX5B]
GO:0006366;transcription by RNA polymerase II;10.0;0.6039883530135606;0.7172351883677006;8.613793447804714;583.8786478812184;3.2909128387363804;0.01954189288791682;0.5835384474769965;[NFIC, INTS4]
GO:0008542;visual learning;8.0;1.0;0.875;9.628524252492122;51.65827414420079;5.970411137910149;0.00172895594617802;0.6803271032452366;[RIC8A]
GO:0006369;termination of RNA polymerase II transcription;9.0;0.8933024483968273;0.8428918493787028;9.5544162803384;477.15162764714074;6.139487467954083;0.015969835568764485;0.7102142998068259;[CPSF2]
GO:0032091;negative regulation of protein binding;5.0;0.6997970393407541;0.6401395315312973;8.48339194818912;32.716075545242866;5.171903441692378;0.0010949776059428606;0.5547323943871747;[GNL3L]
GO:0043392;negative regulation of DNA binding;5.0;0.7586651285174919;0.6695735761196662;8.866384200445225;32.533753988449135;5.788089581116195;0.0010888754675157227;0.5862441822128946;[SUMO3]
GO:0010977;negative regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;494.1264199049594;4.793467005972133;0.016537966589312465;0.6413787507847162;[CIB1, PAFAH1B1]
GO:0045332;phospholipid translocation;8.0;1.0;0.875;9.628524252492122;116.86638763413639;6.641579411751319;0.003911412821194078;0.7146506799819907;[TMEM30A]
GO:0006914;autophagy;4.0;0.6729672293956388;0.5864836146978194;8.39638057119949;37.75222312160081;4.39717627414001;0.001263532933085;0.4748717991491287;[VPS18, VPS41, C6orf106]
GO:0043032;positive regulation of macrophage activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.59742726208806;6.641579411751319;0.004237101960174532;0.6905700452391912;[KARS]
GO:0033619;membrane protein proteolysis;6.0;0.811012628672052;0.7286266269261705;9.260799472366804;49.64990487012002;6.166155715036245;0.001661737633989536;0.6384578026126634;[PARL]
GO:0030220;platelet formation;5.0;1.0;0.7902410118609202;9.628524252492122;33.79744107268718;6.832634648514029;0.0011311699369806302;0.639662265535933;[CIB1]
GO:0070886;positive regulation of calcineurin-NFAT signaling cascade;10.0;1.0;0.9152410118609203;9.628524252492122;339.2927284230194;7.004484905440688;0.011355822276687466;0.7734506956670166;[CIB1]
GO:0019563;glycerol catabolic process;8.0;0.8436909121759173;0.7968454560879586;9.510741216835738;382.0555070212931;7.8311634786251565;0.012787053992369542;0.7754860644832351;[TPI1]
GO:0010976;positive regulation of neuron projection development;9.0;0.6763753087927167;0.7344282795766475;9.14017148457819;493.1928131726474;4.231896183200907;0.016506719612173492;0.6126599927924817;[TMEM30A, DVL3, PAFAH1B1]
GO:0070889;platelet alpha granule organization;6.0;1.0;0.8231203125901445;9.628524252492122;22.861654980906852;9.083926447120524;7.651590180572567E-4;0.7876727335416686;[VPS33B]
GO:0017148;negative regulation of translation;8.0;0.6493065804076676;0.6996532902038338;9.081980546124052;1114.6737408694362;4.99795013456894;0.03730712696566269;0.6305954023103058;[CNOT1, TPR, CNOT10, EIF4E2]
GO:0032525;somite rostral/caudal axis specification;5.0;1.0;0.7902410118609202;9.628524252492122;40.32465619079058;7.474488534686424;0.0013496299528713244;0.6724867031240476;[TMED2]
GO:0034260;negative regulation of GTPase activity;6.0;1.0;0.8231203125901445;9.628524252492122;61.14468506277762;5.970411137910149;0.0020464575824072424;0.6284474158353811;[TMED2]
GO:0061003;positive regulation of dendritic spine morphogenesis;12.0;1.0;0.9481203125901445;9.628524252492122;1908.9696229991087;6.943860283624253;0.06389149532065895;0.8032296504172152;[PAFAH1B1]
GO:0035234;ectopic germ cell programmed cell death;5.0;1.0;0.7902410118609202;9.628524252492122;49.330608194382684;7.9853141584524145;0.001651051061600959;0.6986103492792611;[CASP2]
GO:0009083;branched-chain amino acid catabolic process;8.0;0.7866048967936545;0.7683024483968273;9.387362195675234;378.5048559913599;6.781341354126479;0.012668216897776141;0.7217981122146513;[BCKDHA]
GO:0090267;positive regulation of mitotic cell cycle spindle assembly checkpoint;13.0;0.9326813400603323;0.9288956347978027;9.597752593825367;471.1536740716433;7.8311634786251565;0.015769089460400346;0.8630410292508717;[TPR]
GO:0150012;positive regulation of neuron projection arborization;10.0;1.0;0.9152410118609203;9.628524252492122;614.8715371745376;7.8311634786251565;0.02057919700077474;0.8157270763441555;[DVL3]
GO:0045333;cellular respiration;5.0;0.6799073451904818;0.6301946844561612;8.242229891372231;30.85741402911629;5.572381008289503;0.0010327698776848686;0.5752128357670632;[CHCHD5, FASTKD5, COX5B]
GO:1903214;regulation of protein targeting to mitochondrion;9.0;0.7980440201809971;0.7952626352707877;9.481920778300246;160.31632445447693;5.9928839937622085;0.005365643104166481;0.7027169913188946;[PARL]
GO:0042742;defense response to bacterium;6.0;0.7866048967936545;0.7164227609869718;9.193206181234276;69.6526388451159;4.021331414093558;0.0023312111388408135;0.5287713881179241;[ANKRD17]
GO:0006378;mRNA polyadenylation;10.0;0.9326813400603323;0.8815816818910864;9.582004236857228;472.4435102429282;6.250713103064308;0.015812259116276064;0.734902770639515;[AHCYL1, CPSF2]
GO:0042985;negative regulation of amyloid precursor protein biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;967.9208223894049;7.9853141584524145;0.032395438853188026;0.8046099625986299;[AATF]
GO:1900745;positive regulation of p38MAPK cascade;12.0;1.0;0.9481203125901445;9.628524252492122;1761.632567075866;6.7325511899570465;0.05896025665364957;0.7924232935401965;[KARS]
GO:0006379;mRNA cleavage;8.0;0.8259837884571596;0.7879918942285797;9.474373572664863;348.0101069703874;6.518977089658987;0.01164758509153653;0.7083807915285978;[CPSF2]
GO:0031547;brain-derived neurotrophic factor receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;8.390779266560578;0.0010376185600805164;0.8041048419030481;[SLC9A6]
GO:0051453;regulation of intracellular pH;10.0;0.7192862368539868;0.7748841302879137;9.242861771680136;143.07278219841277;5.407625775213448;0.004788517263036519;0.6917872454856517;[SLC9A6]
GO:0043161;proteasome-mediated ubiquitin-dependent protein catabolic process;9.0;0.7586651285174919;0.775573189439035;9.310070521373587;348.3589749790861;4.015022244900292;0.01165926138982685;0.6015690495021188;[KBTBD4, UBE2I, KCTD10, PSMB1]
GO:2000327;positive regulation of ligand-dependent nuclear receptor transcription coactivator activity;5.0;1.0;0.7902410118609202;9.628524252492122;28.57267182086961;9.083926447120524;9.56301612109344E-4;0.7547934328124444;[CNOT6]
GO:0060716;labyrinthine layer blood vessel development;5.0;1.0;0.7902410118609202;9.628524252492122;85.12843743852892;6.781341354126479;0.0028491721904478507;0.6370391240755715;[TMED2]
GO:0042074;cell migration involved in gastrulation;6.0;0.8259837884571596;0.7361122068187242;9.089527751759436;22.57397290845719;7.212124270218933;7.555305579894227E-4;0.6919486831672181;[RIC8A]
GO:0010507;negative regulation of autophagy;7.0;0.7436939687323844;0.7227663496233927;9.117698628726131;217.48068666745357;5.500407508664414;0.007278882862848883;0.6322104610454062;[HERC1]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[KARS, NFIC, DPF2, DVL3, TMED2, DDX41, AATF, ZNF564]
GO:0016042;lipid catabolic process;4.0;0.5127202928476964;0.5063601464238482;6.883086519318291;43.14795622097559;4.114113147544524;0.0014441232640765526;0.4603959376912539;[PAFAH1B1]
GO:0033962;cytoplasmic mRNA processing body assembly;7.0;1.0;0.8509193652572005;9.628524252492122;107.30488678463786;7.212124270218933;0.0035913979925534566;0.7197477358342742;[ATXN2]
GO:0010501;RNA secondary structure unwinding;7.0;1.0;0.8509193652572005;9.628524252492122;115.0816327851482;5.948432231191374;0.0038516786825735262;0.6551224661907153;[DDX42, DDX41]
GO:0000915;actomyosin contractile ring assembly;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;135.1741411845403;7.9853141584524145;0.004524156856617609;0.7833693374183408;[PDCD6IP]
GO:0090110;cargo loading into COPII-coated vesicle;7.0;1.0;0.8509193652572005;9.628524252492122;99.46684456500904;7.212124270218933;0.0033290657732425078;0.7197477358342742;[SEC24C]
GO:0006468;protein phosphorylation;7.0;0.5708408884191841;0.6363398094667926;8.175090588534603;177.75756772840523;2.970244267288293;0.005949385820444992;0.5028177952168079;[KARS, PTPRA, FASTKD5]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[UBE2I, CNOT1, NFIC, SAP130, TPR, ZNF564]
GO:0045595;regulation of cell differentiation;4.0;0.3376379861120121;0.41881899305600606;5.249000748036359;23.33457331431992;2.3564947222696686;7.809871690777242E-4;0.3705112496850823;[ANKRD17, TMEM30A, DVL3, CIB1, FADS1, PAFAH1B1]
GO:0035459;cargo loading into vesicle;6.0;0.8259837884571596;0.7361122068187242;9.318369324188282;55.50506792578142;6.518977089658987;0.001857704672157885;0.6565011041187423;[TMED2, SEC24C]
GO:0060070;canonical Wnt signaling pathway;8.0;0.6729672293956388;0.7114836146978194;8.391761625343195;31.415129658942366;5.233778845410465;0.0010514361179036673;0.6426556935498979;[DVL3]
GO:0015966;diadenosine tetraphosphate biosynthetic process;10.0;1.0;0.9152410118609203;9.628524252492122;1079.013190642324;8.67846133901236;0.03611360044197283;0.8590579283277371;[KARS]
GO:0035335;peptidyl-tyrosine dephosphorylation;8.0;0.8933024483968273;0.8216512241984136;9.52844079393514;179.24922260518233;5.181953777545879;0.005999310166768488;0.6400053571691908;[PTPRA]
GO:0035457;cellular response to interferon-alpha;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.474488534686424;0.0027327542132076126;0.7053660038532718;[TPR]
GO:0035458;cellular response to interferon-beta;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.004484905440688;0.0027327542132076126;0.6813299963962409;[DDX41]
GO:0042769;DNA damage response, detection of DNA damage;5.0;0.7866048967936545;0.6835434602577475;9.143016436710422;39.83823472227698;6.139487467954083;0.0013333498640710748;0.6042146864874571;[WDR48]
GO:1900087;positive regulation of G1/S transition of mitotic cell cycle;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;354.40743100732976;6.409777797693995;0.011861697769835146;0.7240369598395108;[ANKRD17]
GO:0035690;cellular response to drug;4.0;0.5629771490299041;0.531488574514952;7.020557509946895;41.90713853914268;4.145861845859104;0.0014025942129290189;0.462019567599527;[EFTUD2]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[CNOT6, CNOT1, NFIC, SAP130, DPF2, INTS4, CNOT10, ZNF564]
GO:0038166;angiotensin-activated signaling pathway;6.0;0.8653626801206646;0.7558016526504768;9.4949928598676;26.976932752798508;7.474488534686424;9.028936615729279E-4;0.7053660038532718;[AHCYL1]
GO:0008654;phospholipid biosynthetic process;6.0;0.6073376606709605;0.6267891429256247;8.318602870156806;240.3742781336296;4.22799754278525;0.008045110766327128;0.5393403035501751;[FADS1]
GO:0006355;regulation of transcription, DNA-templated;9.0;0.4043225613388953;0.5984019058497367;6.838723401371219;245.35026186902695;1.5478292109445575;0.008211652463856259;0.4753966830094131;[UBE2I, ZFP91, CIB1, CNOT10, DDX41, AATF, CNOT6, KARS, CNOT1, GOLGB1, NFIC, SAP130, TPR, DPF2, DVL3, FADS1, ZNF564]
GO:0038163;thrombopoietin-mediated signaling pathway;8.0;1.0;0.875;9.628524252492122;32.49393932031223;8.67846133901236;0.0010875429064040555;0.8188169164668168;[CIB1]
GO:0090481;pyrimidine nucleotide-sugar transmembrane transport;7.0;0.7763722522362496;0.7391054913753253;9.097896001429952;63.680604432180516;7.379178354882098;0.002131332521521897;0.728290889492758;[SLC35D2]
GO:0046329;negative regulation of JNK cascade;12.0;0.9326813400603323;0.9144609826203107;9.607904965289386;1764.4523437695266;6.280566066213989;0.05905463204195212;0.7693087532925187;[PAFAH1B1]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[UBE2I, CNOT1, NFIC, SAP130, TPR, DPF2, ZFP91, DDX41, AATF, ZNF564]
GO:0000132;establishment of mitotic spindle orientation;8.0;0.9326813400603323;0.8413406700301662;9.582004236857228;227.84740072539455;6.641579411751319;0.007625847452931234;0.7146506799819907;[PAFAH1B1]
GO:0010603;regulation of cytoplasmic mRNA processing body assembly;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;64.45443428147517;7.57984905034425;0.002157231910176139;0.738553198190834;[ATXN2, CNOT6, CNOT1]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[CASP2, CIB1, AATF]
GO:0010606;positive regulation of cytoplasmic mRNA processing body assembly;8.0;1.0;0.875;9.628524252492122;306.3544197830862;8.16763571524637;0.01025340672906212;0.7926932703116032;[CNOT6, CNOT1]
GO:0006904;vesicle docking involved in exocytosis;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;32.65265176272962;6.039404009397101;0.0010928548690198408;0.6319757144917204;[VPS18, VPS33B]
GO:0033147;negative regulation of intracellular estrogen receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;234.23542340630428;7.138016298065211;0.007839648823214116;0.7400384854347593;[CNOT1]
GO:0070534;protein K63-linked ubiquitination;11.0;0.9326813400603323;0.8987696223598284;9.577230958104572;157.60047254366168;6.166155715036245;0.00527474598481953;0.747766442352181;[ZFP91]
GO:0033145;positive regulation of intracellular steroid hormone receptor signaling pathway;7.0;0.8436909121759173;0.7727648213451592;9.392135474427892;188.04926109035458;6.8867018697843045;0.006293839535346746;0.7031056191423581;[UBE2I]
GO:0009060;aerobic respiration;6.0;0.7671156992804218;0.7066781622303554;8.874752450115741;31.550561209678754;5.926926025970411;0.0010559688900263317;0.6262235851885184;[CHCHD5, COX5B]
GO:0008090;retrograde axonal transport;9.0;0.8436909121759173;0.8180860812682478;9.405380701177911;71.1020239957658;7.004484905440688;0.0023797207554711163;0.7544503089863854;[PAFAH1B1]
